Immuno-Oncology

Product Name: Format/SizeDescriptionsDownload
Immuno-Oncology Library11346 compounds
For cherry-picking
Update: 2016-11
The file contains all available Immuno-Oncology compounds selected from our Signature & BioDesign Libraries. For more information, please download >>>sdf-icon pdf-icon
SL#021
IDO1 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
By utilizing a combination of scaffold hopping and structure-based design strategies ASINEX has developed a library of small molecules for IDO1 drug discovery. Selected compounds have shown significant IDO1 inhibitory activity in vitro as measured in the enzymatic biochemical assays.
Structures are available,"click here"and downlaod "File#1 (1/5) Signature Libraries.
pdf-icon
SL#026
IRAK4 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a series of IRAK4-oriented compounds by combining the IRAK4 hinge binding motif with proprietary natural product-like fragments. Several compounds from this library were screened against IRAK4 kinase in vitro and showed sub-uM IC50. Sunitinib was also included in the library as a reference compound.
Structures are available,"click here"and downlaod "File#1 (1/5) Signature Libraries.
pdf-icon
SL#033
PD1/PD-L1 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has designed a set of novel small molecule probes that can be used for exploration of PD-1/PD-L1 signaling pathway.
Structures are available,"click here"and downlaod "File#1 (1/5) Signature Libraries.
pdf-icon

 

You may also like:

Phenotypic Screening Sets: Format/SizeDescriptionsDownload
Phenotypic Pre-Plated Set14320 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2017-03
ASINEX has created a diverse set of molecules by applying strict physico-chemical and structural descriptors to ensure good solubility and permeability properties. For more information, please download >>>sdf-icon pdf-icon
SL#004
Oncology Phenotypic Screening-1
(Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Release: 2016
ASINEX's oncology-oriented phenotypic library includes compounds based on several scaffolds with proven cytotoxicity (sub-µM EC50 in MTT assay) against a number of cancer cell lines: MV-411 (acute monocytic leukemia), HCT-116 (human colon cancer), MCF-7 (human breast adenocarcinoma‎), A-172 (Human glioblastoma), COLO-320 (colorectal adenocarcinoma), U-937 (histiocytic lymphoma), A-375 (malignant melanoma), BXPC-3 (pancreas adenocarcinoma), U118-MG (malignant glioma), and LN-229 (glioblastoma). Some active compounds were screened in a biochemical assay showing nM level of IC50 against several kinases: Aurora A, Haspin, VEGFR, EGFR, PDGFR.
Structures are available,"click here"and downlaod "File#1 (1/5) Signature Libraries.
pdf-icon
SL#023
Oncology Phenotypic Screening-2
(Colon Cancer/Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Release: 2016
ASINEX has evaluated the susceptibility of several colon cancer cell lines (HCT-116, SW-620, COLO-320, RKO) to a diverse array of small molecules and identified a series of related compounds that kill cancer cells at sub-µM concentrations with limited off target effect on healthy cells (human fibroblasts). Additional screening in a cell-based luciferase reporter assay of Wnt signaling has provided preliminary evidence of Wnt-dependent mechanism of action.
Structures are available,"click here"and downlaod "File#1 (1/5) Signature Libraries.
pdf-icon
SL#035
Oncology Phenotypic Screening-3
(Macrocycles)
80 compounds / set
Pre-Plated Set
Release: 2016
ASINEX has evaluated the susceptibility of several cancer cell lines (i.e. RKO, HCT116, Molt-4, Rs4-11, U937, A549, H1568, H23, PANC1, A2780) to an array of peptidic and non-peptidic macrocycles and identified a series of compounds that kill cancer cells at µM concentrations.
Structures are available,"click here"and downlaod "File#1 (1/5) Signature Libraries.
pdf-icon

Please click here for List of all Signature Libraries.

Top